A 61-year-old woman with multiple metastatic and unresectable gastrointestinal stromal tumors (GISTs) was referred for investigation of refractory hypoglycemia that developed four months before this hospitalization. On admission, her fasting plasma glucose was 38 mg/dL despite 10% glucose infusion. Investigations revealed that her serum C-peptide, insulin and growth hormone levels were suppressed, and big insulin-like growth factor II was observed. She was diagnosed with non-islet cell tumor hypoglycemia, which resolved after glucocorticoid treatment. Clinicians should thus be vigilant to identify hypoglycemia in patients with large metastatic GISTs because glucocorticoid therapy is useful even if the GIST is inoperable.
Introduction
Non-islet cell tumor hypoglycemia (NICTH) is a paraneoplastic syndrome that is diagnosed when a tumor induces hypoglycemia (1). Although Nadler et al. first reported NICTH in primary liver cell carcinoma in 1929 (2), many cases have been reported in recent years. High-molecularweight insulin growth factor II (IGF-II), also known as big-IGF-II or pro-IGF-IIE [68-88] (1, 3), has been considered to be an important inducer of hypoglycemia when secreted from tumors (1). In 1988, Daughaday et al. first described high-molecular-weight IGF-II in a leiomyosarcoma associated with hypoglycemia (4). However, NICTH is mainly caused by mesenchymal tumors, and although gastrointestinal stromal tumors (GISTs) fall into this category, there are few reports of GISTs associated with NICTH. Indeed, the first case of GIST associated with NICTH was reported in 2003 (5), and its characteristics need further clarification.
We herein report a case of hypoglycemia associated with a big-IGF-II-producing GIST and also review the relevant literature.
Case Report
In February 2011, a 61-year-old woman was referred to our hospital for an investigation of refractory hypoglycemia. In March 2010, she reported frequent episodes of lower abdominal pain, which necessitated hospital attendance. Abdominal computed tomography (CT) at that time revealed a massive tumor near her ovary, and an exploratory laparotomy was performed in April 2010. The primary tumor was approximately 10 cm in diameter and was derived from the small intestines rather than the ovary. The tumor had also metastasized throughout the abdomen, including to the small intestine, omentum and both ovaries, but not to the liver or adrenal glands. Therefore, partial resection of the main tumor and ovary was performed, leaving the metastases in situ. Specimens from the resected tumor were pathologically assessed and found to consist of spindle-shaped and epithelioid cells. Immunostaining resulted in a positive finding for the c-kit test ( Fig. 1 ), but other tests were negative for cluster of differentiation (CD)34, desmin, S-100, keratin and calretinin (data not shown). Consequently, the primary tumor was diagnosed as a GIST. The patient was initially treated with imatinib mesylate at a dose of 400 mg/day as adjuvant therapy. Whole-body edema occurred a few months later and the treatment was discontinued. Shortly thereafter, she developed intermittent episodes of dizziness and general fatigue. In October 2010, she presented to the hospital due to sudden unconsciousness caused by low blood sugar, which was treated by an intravenous glucose infusion. Because she reported a one-year history of hypertension treated with 40 mg of telmisartan and 12.5 mg of hydrochlorothiazide, her treatment was changed to 40 mg of nifedipine to rule out drug-induced hypoglycemia. However, the hypoglycemia persisted, and despite treatment with oral glucose products, she presented to the same hospital with a further episode of hypoglycemia-induced unconsciousness in February 2011. She was treated with 10% continuous glucose infusion via a central vein and her consciousness level was restored. She was subsequently referred to our hospital for further investigation of the refractory hypoglycemia.
On admission to our hospital, in February 2011, the results of physical examination were largely unremarkable (height, 151.0 cm; body weight, 49.2 kg; body mass index, 21 .5 kg/m 2 ; body temperature, 36.9 ; and blood pressure, 113/57 mmHg). However, CT scan revealed multiple huge abdominal tumors ( Fig. 2 ). Despite the continuous infusion of 10% glucose, her fasting plasma glucose remained 38 mg/dL. At that time, serum C-peptide, insulin, growth hormone (GH), IGF-1 and IGF binding protein-3 (IGFBP-3) were suppressed. Insulin antibodies were also undetectable ( Table 1) .
On day 2 of admission, her blood sugar profile was 35, 84, 123, 88, 49, 138 and 48 mg/dL at 7:30, 10:00, 11:30, 14:00, 17:30, 20:00 and 23:00, respectively. We then conducted a corticotropin-releasing hormone (CRH) test, which revealed that the cortisol response was almost normal (Table 2). In addition, a growth hormone-releasing peptide 2 (GHRP-2) test was conducted, which showed low basal GH, but with an excessive reaction (Table 2) . She was therefore suspected of having NICTH. Dexamethasone was then administered at a dose of 1 mg/day, which resolved the hypoglycemia, and imatinib mesylate was re-administered at a dose of 400 mg/day. The diagnosis of NICTH was confirmed by Western blot analysis, which revealed big-IGF-II with a molecular weight of approximately 15-20 kDa in her serum before the dexamethasone treatment ( Fig. 3A) . In addition, an immunohistochemistry analysis revealed positive immunostaining for IGF-II in the tumor cells ( Fig. 3B ). After 45 days of admission, she was discharged without the need for intravenous glucose infusion. Fig. 4 summarizes the clinical course during hospitalization.
Discussion
The present case raises two important points. First, during the follow-up for large or metastatic GISTs, clinicians should be vigilant for the occurrence of hypoglycemia. Second, glucocorticoid therapy is useful, even when an inoperable GIST is associated with NICTH. In this discussion section, we place our results in the context of the existing data. The characteristics of 12 patients with GIST and NICTH are summarized in Table 3 , and form the basis of much of this growth hormone, Hb: hemoglobin, Hct: hematocrit, HDL-C: high density lipoprotein cholesterol, IGF-I: insulin-like growth factor I, IGFBP-3: insulin-like growth factor binding protein-3, K: potassium, LDH: lactic dehydrogenase, Na: sodium, Plt: platelets, PT: prothrombin time, RBC: red blood cells, Ret: Reticulocyte, T-Bil: total bilirubin, TC: total cholesterol, TG: triglyceride, TP: total protein, TSH: thyroid stimulating hormone, UA: uric acid, and WBC: white blood cells (Table 3) . Hypoglycemia is an important differential factor that must be ruled out when patients present with a coma because rapid glucose administration can be curative and prevent adverse sequelae. Moreover, when the cause of hypoglycemia is unclear, efforts should be made to identify one. In the present case, both insulin and IGF-I levels were suppressed in the serum, effectively ruling out insulinomas and IGF-I-producing tumors. In addition, drug-induced hypoglycemia, insulin autoimmune syndrome and endocrine-related disorder could safely be ruled out. Finally, identification of big-IGF-II confirmed the diagnosis. The absence of liver metastasis may have antagonized the hypoglycemia (14) .
The annual incidence of GIST (cases per million) has been reported to range from 6.8 in the USA to 14.5 in Sweden (15) . GIST has also been reported to exhibit differentiation toward the interstitial cells of Cajal, which are known as the pacemaker cells of the gastrointestinal tract (7). Most cases of GIST arise in the stomach, small intestine or large intestine, while esophageal cases are rare. In the present case, the GIST was derived from the small intestines and pathologically comprised spindle-shaped and epithelioid cells. Several pathological classification systems exist for GIST, including the Fletcher, Miettinen and modified Fletcher systems (16) . The main tumor measured over 10 cm in diameter in our patient, with an MIB-1 (E3 ubiquitinprotein ligase MIB1) index ! 10% (data not shown) (17) . Therefore, we classified the present case as being at high risk.
As shown in Table 3 , the tumor was detected prior to the occurrence of hypoglycemia in 10 cases (6-12). We previously reported that an attack of hypoglycemia was the presenting feature in 31 of 65 cases (48%) with a large amount of big-IGF-II (18) . Our findings indicate that IGF-II in the GIST nodule and big-IGF-II in the serum were the direct causes of hypoglycemia in the present case. In addition, the disappearance of serum big-IGF-II unresectable and hypoglycemia after successful GIST tumor removal has been reported (4, 19) . Therefore, big-IGF-II might be related to hypoglycemia. Although the number of cases is small, Table 3 suggests that the occurrence of hypoglycemia prior to tumor diagnosis tends to be less common (5, 13) .
Previously, most GISTs were thought to be either leiomyomas or leiomyosarcomas. However, in 1983, Mazur et al. reported the presence of stomach-derived mesenchymal cells, from a gastric stromal tumor (20) . Since then, similar reports have also been considered to represent GISTs, and current diagnostic criteria have been established that utilize immunostaining with the c-kit. Using the current diagnostic criteria, several cases of leiomyosarcoma have been rediagnosed as GIST (7). Therefore, case reports of GIST associated with NICTH may increase in the future.
The role of IGF-II in GIST remains unclear; however, Rikhof et al. recently reported that the expression of big-IGF-II on the surface of GIST cells could be detected in vitro and in vivo (21) . In general, IGF-II plays an important anti-apoptotic role in vitro. In addition, Rikhof et al. reported that, before treatment and during follow-up, 3 of 24 patients showed increased plasma levels of pro-IGF-IIE (68-88), and that all three developed NICTH. Thus, big-IGF-II may be a useful clinical marker in the surveillance of GIST (3), and could have the potential to be a molecular target for treatment.
In the present case, glucocorticoid treatment ameliorated our patient's hypoglycemia, which is consistent with previous reports describing that it is useful for NICTH originating from mesenchymal tumors (1, 22, 23) . In a previous report, Teale et al. reported that glucocorticoid therapy suppressed abnormal secretion of big-IGF-II in a case of NICTH (24) . To understand the effect of glucocorticoid treatment, we must clarify the molecular changes in NICTH.
Generally, IGF-II is thought to have an affinity for proinsulin, binding effectively to insulin receptors. The typical molecular weight of IGF-II is approximately 7.5 kDa, and big-IGF-II is thought to be generated by incomplete processing of pro-IGF-II, the precursor of IGF-II. A ternary complex is formed that is approximately 150 kDa and comprises IGF-II, IGF-binding protein (IGFBP) and the acid-labile subunit, which exist stably in the blood. In NICTH, this ternary complex cannot form because of the excessive molecular weight of big-IGF-II. Therefore, the levels of the IGF-IGFBP binary complex (approximately 50 kDa) and free big-IGF-II increase, whereas those of the ternary complex decrease. This allows free big-IGF-II and the binary complex to pass through the capillary wall, reach the cell surface and connect to insulin receptors (1, 5, 7, 10, 25). Assuming that this molecular mechanism is accurate, the suppression of big-IGF-II is essential in the treatment of NICTH. Big-IGF-II may affect the inhibition of gluconeogenesis in the liver and may promote glucose utilization in muscle. In addition, big-IGF-II may lead to functional reductions in GH and glucagon in the peripheral tissue. As shown in Table 3 , pro-IGF-II (i.e., big-IGF-II) was elevated in five cases, while glucocorticoid therapy was administered only in three cases (including ours). When hypoglycemia presented with a coma, glucose or dextrose infusions were attempted at first in all patients detailed in Table 3 . An alternative medical therapy for NICTH is proposed by the effectiveness of glucagon and GH (1), but neither diazoxide nor octreotide was found to be successful in previous cases (1, 26). As shown in Table 3 , surgical resection, debulking or tumor embolization may be more effective in individual cases. However, we abandoned such intensive therapy in the present case because of our patient's debilitated state.
Imatinib, a tyrosine kinase inhibitor with antineoplastic activity, is the first-line agent for the treatment of GIST, with proven effectiveness even when patients have metastatic or unresectable GISTs (27) . Interestingly, Hamberg et al. have reported that imatinib could worsen hypoglycemia in patients with advanced GIST associated with NICTH (8). Therefore, glucocorticoid therapy in combination with imatinib therapy may be useful.
In summary, we herein described a case of NICTH in a Japanese woman with a big-IGF-II-producing GIST. This case report suggests that clinicians should be vigilant for the occurrence of hypoglycemia in patients with large or metastatic GISTs, particularly given that glucocorticoid therapy is useful regardless of tumor operability. To the best of our knowledge, this is the first case report from Japan on GIST associated with NICTH. However, similar case reports are limited, so further reports are clearly needed.
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